Business
Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting
REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted
About this update from Revolution Medicines, Inc.
[{"type":"text","content":"REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced 11 oral and poster presentations will be featured at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, held from April 25 – 30, 2025. The first clinical data in non-small cell lung cancer from the Phase 1 study of zoldonrasib, a RAS(ON) G12D-selective inhibitor, will be featured in a late breaking oral presentation. Details of the abstracts are listed below: Revolution Medicines Oral Presentations: Title:Preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer (NSCLC) from a Phase 1 study in advanced solid tumorsPresenter:Kathryn Arbour, M.D., Memorial Sloan Kettering Cancer CenterAbstract Number:CT019Session:New Frontiers in Precision OncologyDate/Time:April 27; 5:00 p.m. – 5:15 p.m. CST Title:Discovery of RMC-5127, an oral, RAS(ON) G12V-selective, noncovalent, tri-complex inhibitorPresenter:Anne Edwards, Ph.D.Abstract Number:ND06Session:New Drugs on the Horizon: Part 2Date/Time:April 27; 3:25 p.m. – 3:40 p.m. CST Revolution Medicines Poster Presentations: Title:Early reduction in circulating tumor DNA (ctDNA) is associated with clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC)Presenter:Jia Luo, M.D., Dana-Farber Cancer InstituteAbstract Number:LB218Session:Late-Breaking Research: Clinical Research 1Date/Time:April 28; 2:00 p.m. – 5:00 p.m. CST Title:Mechanisms of resistance to the RAS(ON) multi-selective inhibitor daraxonrasib (RMC-6236) in RAS mutant PDAC and potential resolution with RAS(ON) combination therapiesPresenter:Mallika Singh, Ph.D.Abstract Number:LB281Session:Late-Breaking Research: Experimental and Molecular Therapeutics 3Date/Time:April 29; 9:00 a.m. – 12:00 p.m. CST Title:Combination of RAS(ON) mutant-selective and multi-selective inhibitors sensitizes immune-refractory, RAS-driven preclinical models to immunotherapyPresenter:Mariela Moreno Ayala, Ph.D.Abstract Number:6046Session:Adaptive Immunity in Tumors / Oncogenic Pathway-Mediated Regulation of Inflammation and Tumor ImmunityDate/Time:April 29; ...